Gh Research Plc (GHRS)
NASDAQ:GHRS
Want to see GHRS full AI Analyst Report?
GHRS Stock Chart & Stats
$18.34
-$0.22(-2.41%)
At close: 4:00 PM EST
$18.34
-$0.22(-2.41%)
Day’s Range― - ―
52-Week Range$11.32 - $25.94
Previous CloseN/A
Volume14.35K
Average Volume (3M)252.68K
Market Cap
$1.71B
Enterprise Value$1.40B
Total Cash (Recent Filing)$267.32M
Total Debt (Recent Filing)$432.00K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 26, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding68,557,175
10 Day Avg. Volume297,182
30 Day Avg. Volume252,676
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.01K
Enterprise Value/Ebitda-24.02
Forecast
1Y Price Target
$39.50Price Target Upside115.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage With Substantial EquityGH Research's extremely low leverage and sizable equity base provide structural financial resilience for a clinical-stage biotech. This reduces insolvency risk during multi-year pivotal programs, supports R&D spending without large interest burdens, and improves flexibility to execute clinical plans.
Peer‑reviewed Phase 2b Clinical ValidationA peer-reviewed Phase 2b in JAMA Psychiatry materially strengthens the scientific case for GH001. Durable, severity-independent efficacy and published data raise the probability that Phase 3 designs will gain regulatory and investigator support, improving long-term commercialization prospects if replicated.
Recent Successful Equity Raise Increases RunwayThe $111M underwritten offering meaningfully extends financial runway for late-stage development and pre-commercial work. This capital reduces immediate financing pressure, allowing the company to progress pivotal programs and device development with less short-term disruption to trial timelines.
Bears Say
No Product Revenue And Widening LossesGH Research remains pre-revenue with escalating net losses, reflecting higher R&D and G&A as programs scale. Without commercial sales, recurring losses will continue to pressure equity and require external funding, making long-term sustainability contingent on successful late-stage outcomes or partner deals.
Negative Operating Cash Flow And Rising Cash BurnPersistently negative operating and free cash flow indicates cash burn has increased as trials and development scale. This structural cash outflow limits optionality, can accelerate financing needs ahead of pivotal readouts, and raises execution risk if market conditions or funding access tighten.
Dependence On Equity Financing Creates Dilution RiskFrequent reliance on equity markets and an ATM facility creates structural dilution risk for shareholders and ties funding capacity to market appetite. Over time this can erode existing ownership stakes and shareholder returns if multiple raises are required before commercialization or partnering.
GH Research News
GHRS FAQ
What was Gh Research Plc’s price range in the past 12 months?
Gh Research Plc lowest stock price was $11.32 and its highest was $25.94 in the past 12 months.
What is Gh Research Plc’s market cap?
Gh Research Plc’s market cap is $1.71B.
When is Gh Research Plc’s upcoming earnings report date?
Gh Research Plc’s upcoming earnings report date is Aug 26, 2026 which is in 83 days.
How were Gh Research Plc’s earnings last quarter?
Gh Research Plc released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.293 by -$0.017.
Is Gh Research Plc overvalued?
According to Wall Street analysts Gh Research Plc’s price is currently Undervalued.
Does Gh Research Plc pay dividends?
Gh Research Plc does not currently pay dividends.
What is Gh Research Plc’s EPS estimate?
Gh Research Plc’s EPS estimate is -0.32.
How many shares outstanding does Gh Research Plc have?
Gh Research Plc has 68,557,175 shares outstanding.
What happened to Gh Research Plc’s price movement after its last earnings report?
Gh Research Plc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.293. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of Gh Research Plc?
Currently, no hedge funds are holding shares in GHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (115.38% Upside)
$39.50 (115.38% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.23%
12-Months-Change
Fundamentals
Return on Equity
-19.83%
Trailing 12-Months
Asset Growth
-14.10%
Trailing 12-Months
Company Description
Gh Research Plc
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$39.50
▲(115.38% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
3.78% Mutual Funds
54.97% Other Institutional Investors
40.38% Public Companies and Individual Investors